<?xml version="1.0" encoding="UTF-8"?>
<p>Lopinavir/ritonavir combines two protease inhibitors, the latter used to pharmacokinetically ‘boost’ lopinavir concentrations and prolong the effect through CYP3A4 inhibition.
 <xref rid="apt15779-bib-0104" ref-type="ref">
  <sup>104</sup>
 </xref> Licensed as an HIV treatment, in vitro and animal model use in SARS and MERS‐CoV resulted in a lower risk of ARDS, lower viral load in lung and extrapulmonary tissue and reduced mortality.
 <xref rid="apt15779-bib-0104" ref-type="ref">
  <sup>104</sup>
 </xref>, 
 <xref rid="apt15779-bib-0105" ref-type="ref">
  <sup>105</sup>
 </xref>, 
 <xref rid="apt15779-bib-0106" ref-type="ref">
  <sup>106</sup>
 </xref> Results from a recent human trial in China did not demonstrate a statistically significant improvement in time to discharge or clinical improvement. However, treatment was commenced late in the diseases course and only in patients who had developed very severe disease.
 <xref rid="apt15779-bib-0107" ref-type="ref">
  <sup>107</sup>
 </xref> Further trials are needed to determine the utility of this medication regime. Importantly lopinavir/ritonavir inhibits the metabolism of corticosteroids, tacrolimus, ciclosporin and tofacitinib which may lead to toxicity (Table 
 <xref rid="apt15779-tbl-0004" ref-type="table">4</xref>).
</p>
